Indivior Non-GAAP EPS of $1.32 beats by $0.19, revenue of $356M beats by $26.65M (INDV:NASDAQ)
Indivior (INDV) reported Q3 Non-GAAP EPS of $1.32, exceeding estimates by $0.19. Revenue grew 13.4% year-over-year to $356M, surpassing expectations by $26.65M. SUBLOCADE net revenue reached a record $267M, up 22% year-over-year. The company's FY26 revenue consensus is $1.33B.
How this was made
The 30-second read
Why it matters
The earnings beat is a primary disclosure that can move the stock in the short term.
Market read
The earnings surprise provides a fresh trading catalyst for INDV, likely prompting short-term price action.
What to watch
Future guidance and pipeline updates are not disclosed, which could temper enthusiasm.
Background
Indivior Pharmaceuticals, a specialty pharma company, released its Q3 2026 earnings via a press release.
Ticker impact
Indivior reported Q3 Non-GAAP EPS of $1.32, beating expectations by $0.19 and revenue of $356M, beating by $26.65M.
likely upward pressure as the market prices in the earnings beat
Both EPS and revenue exceeded consensus, which typically drives short-term buying interest.
Market effects
The pharma sector may see modest uplift as a peer demonstrates strong earnings.
U.S. markets could open higher on the earnings surprise.
Limited to investors tracking U.S. biotech and specialty pharma stocks.
Counterpoint
If the beat is already priced in, the stock could face a pullback.
Key entities
- companyIndivior Pharmaceuticals, Inc.
U.S.-listed specialty pharmaceutical company reporting Q3 earnings.
